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ABSTRACT
Hundreds of compounds have been tested over 
the years in a search for adjuvants to incorporate 
with antigens or allergens to enhance the immune
response. Despite this, aluminum salts have been the
only adjuvants that have been both registered for 
clinical application and used on a large scale until
recently. Salts of aluminum, such as aluminum
hydroxide, have been used as general immunologic
adjuvants for several decades. Some allergen vaccines
used for the treatment of allergy are still formulated
with aluminum-based adjuvants. These formulations
have generally proved efficacious and have a good
safety profile compared with simple aqueous extracts.
However, there is reported sensitivity and toxicity asso-
ciated with use of aluminum. In addition, aluminum
salts are known to be potent stimulators of T helper (h)
2 cell activity. Because Th2 activity directs towards an
allergic response, aluminum salts are potentially
counterproductive when used as adjuvants in the
immunologic treatment of type 1 hypersensitivity.
Many soluble and insoluble molecules have been
reported to have adjuvant activity in experimental
systems. Some of these have been used clinically, but
side effects, such as local granuloma formation, have
led to their withdrawal from clinical use. Newer depot-
type adjuvants, such as insoluble calcium salts,
tyrosine (now registered) and coupled alginates, may
eliminate some of the potential problems of aluminum
salts and are currently used in some allergy vaccines
but have not as yet formed a complete replacement.
Liposomes, iscoms and biodegradable microspheres
are now being considered for clinical use as adjuvants
for both oral and parenteral routes. Soluble adjuvants
that are capable of directing the immune response in a
more selective way are currently in development for
use in allergy vaccines. One of these, the Th1-directing
adjuvant monophosphoryl lipid A (MPL®; Corixa,
Seattle, WA, USA), is now in clinical use in allergy vac-
cines formulated with the depot adjuvant L-tyrosine.
Other ways of stimulating a Th1 response using
immunostimulatory DNA sequences (immunostimula-
tory DNA sequences (ISS) or CpG motifs) as ‘built-in’
adjuvants are being studied. Further interesting adju-
vants reported in the literature, such as Montanide ISA
720, SAF-m, RC-529 and QS21, may also be applica-
ble to allergy vaccination.
Key words: adjuvant, allergy, aluminum salts,
immunotherapy, monophosphoryl lipid A, T helper 1
cells, T helper 2 cells.
INTRODUCTION
It is now 70 years since Glenny1 showed that alum-
precipitated diphtheria toxoid was more immunogenic 
in laboratory animals than an aqueous presentation of
toxoid. Since then, various aluminum compounds have
been used as immunologic adjuvants in vaccines, such as
those used to protect against diphtheria, tetanus, typhoid
and pertussis, and they are widely used substances for
this purpose. Until recently, aluminum compounds were
the only adjuvants permitted in vaccines for the prophy-
laxis of infectious disease and toxemia.
The use of these aluminum compounds was extended
to allergy vaccines by Sledge2 and alum salts have been
the mainstay as far as depot adjuvants have been con-
cerned for a long time. Some allergy companies continue
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to provide certain product ranges of alum-adsorbed aller-
gens for allergy vaccination (AV) and there is substantial
evidence that these products can be effective in reducing
allergic symptoms in appropriately diagnosed and treated
patients.3 The extensive use of alum as an adjuvant in
allergy and prophylactic vaccines over many years has led
to a large accumulation of information on its benefits and
some of its drawbacks compared with the limited knowl-
edge available of other adjuvants. Hence, alum features
prominently in the present review. A number of problems,
including tolerance, have been associated with the use of
alum. Although the levels of aluminum permitted in injec-
tions are limited (e.g. by the European Pharmacopoeia) 
to 1.25 mg per dose,4 the induction of sensitivity to alu-
minum has still been reported in some patients. There is
an increasing requirement for standardization of final
product forms used for AV. However, meaningful quality
assurance measurements of the potency of these vaccines
are problematic owing to difficulties in the recovery of
allergens adsorbed to the alum. Alum is known to be an
efficient T helper (h) 2 cell inducer, which may potentially
exacerbate rather than alleviate the allergic condition,
although in practice the evidence that alum reduces the
efficacy of treatment is weak.
It may be time now to consider replacing alum com-
pounds with other more selective molecules, possibly of
biological origin. This publication also describes some of
the adjuvants that were used previously but are no longer
permitted, newer depot formulations and particulate
adjuvants being researched and other adjuvants that are
already in use for the treatment of type 1 hypersensitivity.
In particular, the review discusses some of the more
modern approaches towards the selective stimulation 
of key components of the immune system (e.g. Th1 cells)
by soluble adjuvants, such as monophosphoryl lipid A
(MPL), currently used in a novel allergy vaccine, and
studies with immunostimulatory DNA sequences (ISS)
coupled with major allergens.
RATIONALE FOR THE INCLUSION OF ALUMINUM
SALTS IN VACCINES
The salts of aluminum that are used most frequently to
adjuvant allergy and other vaccines are aluminum potas-
sium sulfate (alum), aluminum hydroxide and aluminum
phosphate. These salts are often generically referred to as
‘alum’ and that convention is used in this report.
Alum is a component of AV formulations, first as a
depot formulation, enhancing the induction of an
immune response and allowing a reduction in the dose of
allergen and fewer injections compared with aqueous
regimes. Second, the slow-release characteristics of the
preparation reduce the immediate and potentially dan-
gerous reaction of injected allergens with IgE antibodies
on mast cells and basophils. These are the rationales for
the use of depot adjuvants generally.
It is clear that alum can enhance the induction of a
primary response to the included allergen or antigen. It is
probable that the slow-release characteristics of the
preparation contribute to this effect5 but, in addition, the
particulate nature of alum adsorbates is likely to enhance
the induction of an immune response. It was demon-
strated by Mannhalter et al.,6 using tetanus toxoid, that a
very much greater amount of antigen was associated with
macrophages when the tetanus toxoid was adsorbed to
aluminum hydroxide rather than presented in a soluble
form. They concluded that in the early phase of the
immune response alum probably exerts its effect at the
level of the antigen-presenting cell (APC). This enhance-
ment is not so apparent when alum-adsorbed antigen is
used to induce a secondary immune response.5 IgE-
mediated allergy is characterized by a well-established
immune response to the offending allergens, so specific
immunologically based treatment is also targeted
towards effecting some change during a secondary type
stimulus. Therefore, the use of alum at this stage for its
immunostimulatory properties alone may not be appro-
priate for AV.
SENSITIVITY TO ALUMINUM
Alum-adsorbed allergens have been reported to induce
local adverse events during AV. Of course, allergens
themselves may induce a local reaction particularly when
long-term depot-type adjuvants are used. Local reactions
sometimes include both painless and painful local
swellings and abscess formation, which are short lived or,
rarely, more long-lived fibroses. These foci may some-
times reactivate after several years despite there being no
measurable aluminum in biopsies of the sites.7
Sensitivity can be induced to aluminum itself from 
the use of AV containing alum salts as adjuvants.
Clemmensen and Knudson8 confirmed this by patch
testing, which demonstrated that sensitivity (probably
delayed) could be induced by AV with an alum-adsorbed
grass pollen extract. Two similar cases were reported by
Castelain et al.,9 who described patients with pruritis of
the arms following AV with alum-adsorbed allergens. The
patients also had persistent nodules, which were shown
to contain large amounts of aluminum.
In a further study of alum-adjuvanted AV,10 children
were observed to develop persistent excoriated papules
and subsequent patch tests to AlCl3 were positive in nine
of 13 cases. The authors concluded that aluminum is
most likely to sensitize when injected in preparations used
for immunization rather than when taken in through other
routes. Frost et al.11 performed a follow-up study in 
202 children monitoring 1–3 years after cessation of
treatment with alum-adsorbed allergens. They found that
13 children had severely pruiginous treatment-resistant
nodules. The nodules in six of these cases were examined
further and shown to consist of germinal centres, five
having aluminum crystals scattered both between the
cells and within the phagosomes of macrophages. Patch
testing showed sensitivity to aluminum in four of six cases.
Although induction of sensitivity to aluminum is rela-
tively rare, it should be considered as a possible adverse
event following alum-adjuvanted AV. Obviously, treat-
ment involving maintenance therapy or successive
courses could increase the likelihood of induction of
aluminum sensitivity.
OTHER POSSIBLE TOXIC EFFECTS OF ALUMINUM
Other potentially damaging effects of alum should be
considered before treatment.
The uptake of aluminum into soft tissue, such as spleen
and liver in patients with renal failure, may further an
entry into the reticuloendothelial system and, so, cause a
possible immunosuppressive effect. This has been high-
lighted as a situation that should be prevented by
avoiding an increased loading of aluminum12 in certain
patients.
Vogelbruch et al.13 showed that poor injection tech-
nique, in which aluminum salts were localized at an
intradermal site, could lead to persistent intradermal
granuloma formation with consecutive dermal necrosis. It
was concluded that this was not likely to be an allergic
reaction to aluminum.
The possible implication of aluminum for induction of
Alzheimer’s disease should also be considered.14
IMMUNE ENHANCEMENT BY ALUMINUM-
CONTAINING ADJUVANTS
There is no doubt that alum adjuvants are capable of
enhancing the specific immune response to an adsorbed
antigen. Therefore, alum is used regularly in the immu-
nization of experimental animals, in particular to induce
IgE antibody responses in mice and rats through its
propensity to stimulate preferentially Th2 cell activity.15
This infers that alum is an inappropriate adjuvant to use
for the treatment of IgE-based allergy, where it may be
expected to make the condition worse. However, if, as
suggested above, alum has very little effect on the sec-
ondary response, then its Th2 cell-inducing properties
may be of no consequence in AV. There is some contrary
evidence that the addition of alum to both the primary
immunization and a booster injections of pertussis
vaccine, itself a Th2 adjuvant, can induce IgE antibody 
to the antigen.16 There is no firm evidence that alum-
adsorbed allergens exacerbate the symptoms of allergy
when used for AV; in fact, it is accepted by many that an
adequate hyposensitizing effect can be achieved with
such products.
ALTERNATIVES
Aluminum salts have stood the test of time as depot adju-
vants for use in AV vaccines. Their long use has enabled
a vast body of knowledge to be accumulated regarding
their properties and, not surprisingly, both beneficial 
and occasionally adverse effects have been reported.
Although side effects occurred in relatively few patients,
and their use should be avoided in some circumstances,
their ability to provide generally a safer and more effica-
cious therapeutic effect than an equivalent aqueous
formulation is accepted by many specialists. Their IgE-
inducing properties in animals have cast some doubt 
on their use, although no definitive proof is available
that this can exacerbate the allergic state in humans.
However, other more appropriate adjuvants are now
available for use in allergy vaccines and others should be
considered for the future.15
It is of interest that it is in the allergy field that most
progress has been made in the introduction of newer
forms of adjuvant with several different molecules, albeit
mainly those that form depot formulations, currently used
in allergy vaccines.
The naturally occuring amino acid L-tyrosine, which
acts as an adsorbent for allergen extracts, has been used
successfully for some years as a depot form for AV.17
Allergy vaccines prepared this way have been registered
with a number of regulatory authorities. This amino acid
is relatively insoluble at neutral pH and, therefore, aller-
gens or, indeed, antigens can be coprecipitated with the
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tyrosine or adsorbed onto preinsolubilized tyrosine. 
Such a product has the clear advantage over alum salts
because it is metabolizable, with a half-life at the site of
injection of approximately 48 h. It is of particular interest
that tyrosine stimulates the induction of an IgG isotype
pattern in mice more consistent with Th1 cell stimulation
compared with the Th2-like effects seen when alum is
used as an adjuvant. Some more hydrophobic derivatives
of tyrosine have been shown to have even more powerful
adjuvant effects in experimental systems, but have not as
yet been developed further.18
Calcium salts, in particular calcium phosphate, are
also available for the same purpose. Clinical results have
indicated the usefulness of AV vaccines adjuvanted this
way and a good safety profile is apparent.19
One of the most interesting approaches has been to
couple allergens to larger molecules. Alginate is an
example of one of these molecules and a soluble and
successful range of AV products based on this principle
has been available for several years.20
FAILURES OF THE PAST
A comprehensive search through the relevant patent liter-
ature reveals many hundreds of soluble and insoluble
materials with immune-enhancing properties as dem-
onstrated in in vivo and in vitro systems. A complete
appraisal of all these possibilities is outside the scope of
the present review; however, it is worth quoting some
examples of the approaches that failed for various
reasons.
Depot adjuvants based on Freunds adjuvant21 have
been used in experimental systems and at various times
have been introduced into the clinic. The principle is one
in which allergens are usually prepared in an aqueous
phase and an emulsion made by the addition of oil and
an emulsifying agent. The source of the oil and emul-
sifying agent has usually directed whether the product 
is clinically acceptable. For example, mineral oils have
been rejected, whereas vegetable oils, such as peanut oil
(Adjuvant 65),22 were considered more acceptable some
time ago. Vaccines made this way have often had a good
immunogenic profile, were efficacious and helped to
prevent treatment-induced anaphylactic side effects when
used for AV of allergic patients. However, local lesions
have, until now, prevented their introduction on a pro-
longed routine basis.
Various soluble molecules, in particular those derived
originally from bacterial cell wall sources, such as
muramyl dipeptide23 and its many analogs, were also
believed to have great promise as adjuvants, but the
potential toxic effects have never been separated satisfac-
torily from the desirable immune-stimulatory properties.
Other molecules with innate adjuvant properties, 
such as macrophage-stimulating activity, have actually
been coupled to the antigen or allergen of interest in 
an attempt to limit these biological properties solely 
to enhancement of the immune response to that anti-
gen or allergen. For example N-formyl-methionyl-leucyl-
phenylalanine was coupled covalently to allergens and
shown to have potentially useful effects in experimental
animal systems.24 Unfortunately, none of these promising
developments has ever been progressed satisfactorily to
enable them to be used regularly in humans.
ADJUVANTS OF THE FUTURE
More exciting products that can entrap allergens, such as
liposomes, iscoms and biodegradable microspheres,25
are in development with the possibility that they may
induce Th1 cell activity. It has been suggested that such
particles could be useful for both oral and parenteral AV.
Control of particle size and constituents added during
manufacture can impart properties relevant for stimula-
tion of the common mucosal immune system via M cells
in the intestine or other sites or provide a formulation that
is readily attractive to APC. Reproducibility of manufac-
turing processes has slowed their progression to regular
clinical use.
Despite the earlier disappointments in the developments
of emulsions, it is known that a number of such products
with an improved safety profile over the earlier examples
are now under study for use as a means of adjuvanting
vaccines against pathogenic organisms. Squalenes (metab-
olizable carbohydrates related to cholesterol) are showing
promise. The oil-in-water preparation MF59 has been eval-
uated in vaccines for various pathogens (e.g. in HIV vaccine
clinical studies).26 The chemically related adjuvant SAF-m
has been investigated in clinical trials for the immunother-
apy of melanoma.27 The water-in-oil adjuvant Montanide
ISA720 is another metabolizable oil that has been clinically
evaluated when incorporated with recombinant malarial
antigens.28 No doubt, it will not be long before some of
these will be also studied for their potential to enhance the
efficacy and safety profiles of allergy vaccines.
Saponins (triterpenoid glycosides) have been used
exclusively for some time as veterinary adjuvants, without
progression to human use due to toxic properties, such as
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hemolytic effects on red blood cells. However, the safety
aspects have now improved significantly as a result of
purification measures29 and a purified saponin QS21 has
been evaluated in both infectious disease and cancer
vaccines.30
Allergy is now believed to be mediated by an imbal-
ance between allergen-specific Th1 and Th2 cells, with
an excess of Th2 cell activity.31 Cytokines from Th2 cells,
such as interleukin (IL)-4 and IL-13 are believed to lead 
to a raised IgE levels32 and IL-5 and others to the
eosinophilia and related late-phase response of allergy.33
Intuitively, therefore, adjuvants that preferentially support
Th1 responses to associated antigens would be can-
didates as adjuvants to correct the T cell balance and,
thus, would have potential utility in allergy vaccination.
One of the most fascinating recent developments 
has sprung from the observation during investigations of
immunization of mice with antigen DNA that certain
bacterial immunostimulatory DNA sequences (ISS or
CpG motifs) can act as Th1 adjuvants, as demonstrated
by antibody and cytokine induction.34 Following gene
immunotherapy with plasmid DNA (pDNA) encoding 
β-galactosidase, CD4+ T cells were stimulated with
antigen in vitro, resulting in IgG2a induction and produc-
tion of interferon (IFN)-γ, but no IL-4 or IL-5 were
released. In the same experiment, IgE and IgG1 were
induced by β-galactosidase in alum and, in contrast, 
IL-4 and IL-5 were released and no IFN-γ was detected.
The Th1 response was found to be resulting from a non-
coding sequence (ISS) in the backbone of the pDNA.
Advantage has been taken of this finding by coupling a
non-coding ISS directly with single recombinant aller-
gens, such as Amb a 1,35 or by coadministration in the
case of Cry j 1 and Cry j 2.36 DNA vaccination of mice
with plasmid DNA coding for Cry j 1 has also been seen
to produce a Th1 response in mice.37 Although experi-
mental data suggest that these are appropriate forms for
AV, the practicalities associated with the number of sepa-
rate products required and the cost of obtaining full data
for registrations of each may be prohibitive.
A new generation of soluble adjuvants, derived from
detoxified bacterial cell wall components and originally
designed for use with bacterial, viral and oncology vac-
cines, is currently under study. These compounds have
the potential to enhance the status of allergen-specific
immunotherapy because of their capacity to induce the
production of a more Th1 cell-like rather than Th2 cell-
like profile of cytokines.38 One of these, monophosphoryl
lipid A (MPL®; Corixa, Seattle, WA, USA), has been
included as an adjuvant in allergy vaccines.39 MPL® is 
a lipopolysaccharide extracted from the cell wall of
Salmonella minnesota. It is detoxified by acid and
organic/alkali treatment and highly purified by high-
pressure liquid chromatography. The pure well-
characterized product is composed of analogous molec-
ular species (congeners) having different fatty acid side
chains. The novel adjuvant is a component of a mel-
anoma vaccine, Melacine® (Corixa, Seattle, WA, USA),
registered in Canada40 and has been studied in infectious
disease vaccines.41–43 MPL® has been shown to activate
APC, probably through TLR4 (toll receptor for lipo-
polysaccharide). It enhances phagocytosis, upregulates
major histocompatibility complex (MHC) class II mole-
cules on APC and causes release of IL-12, IL-1, tumor
necrosis factor-α and granulocyte–macrophage colony
stimulating factor from APC. Interferon-γ and IL-2 are
released from Th1 cells probably indirectly via the effects
of IL-12.44
Allergy vaccines have been developed containing both
birch, grass, Parietaria and olive pollen extracts with
reduced IgE-binding activity (allergoids), which are co-
adsorbed with MPL® to insoluble tyrosine. It is known that
analogous products to treat allergy to ragweed and
Japanese cedar pollen and to house dust mite are under
development. The combination of MPL® adjuvant and
tyrosine has been shown, in animals, to be synergistic in
terms of antibody and Th1 cell induction.45 Cytokine
changes consistent with a Th2/Th1 reorientation have
been reported in clinical trials. In particular, an increase
in INF-γ and a reduction in the seasonally induced rise
normally seen in IL-4 and IL-5 release from allergen
stimulated T cell clones were observed after therapy.46
Lymphocyte proliferation tests have shown an immediate
rise in total lymphocyte responses after treatment, but
only with respect to allergen-specific stimulation, fol-
lowed later to a fall below the baseline,47 possibly due to
an increase of IL-10 expression. Specific IgG antibody
was raised and the normal specific IgE antibody rise
expected following the first years treatment with other
allergy vaccines did not occur. It is of note that the sea-
sonal rise in specific IgE seen in placebo-treated patients
was eliminated by the active product.39 A very strong Th1
response, particularly associated with Gram-negative
bacteria and viruses, is sometimes associated with
delayed hypersensitivity. No local 24 h delayed hypersen-
sitivity reactions developed during the injection regimen
and there were no systemic or respiratory side effects con-
sistent with a type IV hypersensitivity response. Adverse
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events reported were qualitatively and quantitatively no
greater than those seen with more conventional allergy
vaccines. The enhanced efficacy obtained in placebo-
controlled clinical studies facilitated a reduction in the
number of injections required for treatment from the
many often used with current vaccines to only four pre-
seasonal treatments.39 This approach is of value in terms
of increased patient and doctor compliance and brings
obvious pharmacoeconomic advantages. Allergy vac-
cines containing MPL® are now available in some
European countries.
Sublingual immunotherapy (SLIT) is growing in pop-
ularity as a treatment for respiratory allergy48 due to the
apparent lack of side effects and patient compliance.
Although the immunologic mechanisms responsible for
the beneficial effects are still not clear, the possibility of
local adjuvants being used to enhance the efficacy of
treatment is already being considered and the search is
on for materials with the relevant properties. MPL® has
already shown a potential in experimental animals to
promote a Th1-like serum antibody profile and IgA anti-
body in the secretions to an associated antigen delivered
by the mucosal route.44 One may argue over the defini-
tion of adjuvants, but there are other novel ways of
potentially enhancing the immune response to SLIT.
Penetration enhancers (e.g. fatty acids, bile salts, surfac-
tants) are under investigation,49 as are bioadhesives
(e.g. chitosan, carbopols), which promote absorption to
mucosal surfaces.50 The use of either of these two strate-
gies could elevate the very low uptake of antigen that is
achieved by existing SLIT but, of course, the safety and
tolerance aspects would have to be very carefully evalu-
ated. If any of the above approaches to treatment
become proven, then the whole area of allergy vaccina-
tion may be extended from its current niche position to a
first-choice therapy in well-diagnosed patients.
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